We saw numbers that had the near term in the $400M area near term with growth toward $1B in a report that was posted here recently.
The company PR is high-balling the opportunity as it did with ABSSSI. It's not anywhere near a $2.5B market any time soon. If you believe it is, then why did we sell half the company to raise shoe-string funds over the last 18 months rather than sign a deal on a $2B/year indication?
Same could be said for B-ABSSSI. Drawing comparisons to $1B/year Daptomycin (Cubicin) sales was very far from the reality of what B-ABSSSI could bring. If not, then why have we sold nearly 75% of the company to fund ourselves to this point rather than sign a deal on B-ABSSSI?
We're either dealing overly optimistic market data that potential partners don't agree with, or one hell of an atrocious negotiator. From the B-UP deal I'm not sure which it is but I'm guessing both.
We really need one solid deal to get our feet on solid financial footing to get credit for everything in the pipeline. As of yet, Leo has been unwilling or unable to make it happen.
Go IPIX!
News 
Market Data 
Discover 
AI
